Name | Irbesartan |
Synonyms | AVAPRO APROVEL CS-1097 SR-47436 SR-47436 Irbesartan IRBESARTAN BMS-186295 BMS-186295 Irbesartan (GMP) 2-butyl-3-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one 3-butyl-2-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE |
CAS | 138402-11-6 |
EINECS | 604-078-2 |
InChI | InChI=1/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) |
Molecular Formula | C25H28N6O |
Molar Mass | 428.53 |
Density | 1.30±0.1 g/cm3(Predicted) |
Melting Point | 180-181°C |
Boling Point | 648.6±65.0 °C(Predicted) |
Flash Point | 346°C |
Solubility | Soluble in DMSO (>25 mg/ml), ethanol (~0.5 mg/ml), methanol, DMF (~20 mg/ml), and water |
Vapor Presure | 1.05E-16mmHg at 25°C |
Appearance | White to white-like powder |
Color | white to off-white |
Merck | 14,5083 |
pKa | 4.16±0.10(Predicted) |
Storage Condition | 2-8°C |
Refractive Index | 1.689 |
MDL | MFCD00864464 |
Physical and Chemical Properties | Crystallization from 96% ethanol, melting point 180-181 °c. |
Use | Antihypertensive drugs. Angiotensin II-l (A II 1)-receptor antagonist. For the treatment of high blood pressure. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | HM2950270 |
HS Code | 29332900 |
Reference Show more | 1. [IF=2.629] Yang Xiaomei et al."Protective Effect of Keluoxin against Diabetic Nephropathy in Type 2 Diabetic Mellitus Models."Evid-Based Compl Alt. 2021;2021:8455709 2. [IF=5.811] Zhenchao Niu et al."Evaluation of Potential Herb-Drug Interactions Between Shengmai Injection and Losartan Potassium in Rat and In Vitro."Frontiers in Pharmacology. 2022; 13: 878526 |
white or off-white crystalline powder; Odorless. Crystallization from 96% ethanol, melting point 180~181 °c. Slightly soluble in methanol, chloroform, almost insoluble in water.
1 A (fluorenylmethoxycarbonylamino) cyclopentanecarboxylic acid to 4-(2-phenylcyano) benzylamine amidation reaction, the product hydrolysis to remove the protective group on N, it is condensed with triethyl orthobutyrate and then reacted with sodium azide to obtain irbesartan.
was first developed by Sanofi and BMS and was approved by the European Union for marketing in the United Kingdom in 1997. Antihypertensive drugs. Angiotensin II type 1 (A II 1)-receptor antagonist. Can inhibit vasoconstriction and the release of aldosterone, resulting in antihypertensive effect. For the treatment of high blood pressure. It is a new antihypertensive drug with good effect and little adverse reaction.